TSX-V:COV - TSX Venture Exchange - CA22282D3022 - Common Stock - Currency: CAD
TSX-V:COV (2/21/2025, 7:00:00 PM)
2.8
-0.38 (-11.95%)
The current stock price of COV.CA is 2.8 CAD. In the past month the price decreased by -11.95%. In the past year, price increased by 93.1%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 261.54M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 188.23M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 185.09M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 121.39M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 89.95M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 82.42M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 78.27M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 48.5 | 65.22M | ||
MDCX.CA | MEDICUS PHARMA LTD | N/A | 61.74M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 52.45M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 51.96M | ||
HEM.CA | HEMOSTEMIX INC | N/A | 25.50M |
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of patent-protected medical products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-09-03. The firm's solutions are designed for patients and made for care providers. The firm leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon's name, and by developing and commercializing medical products for other medical companies under development and license contracts. The firm has three proprietary platform technologies that have the potential to be developed into a number of medical devices and products: Collagen matrix, Antimicrobial silicone adhesive and Medical coatings. Its product type includes advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, and perioperative dressings. Its brands include ColActive PLUS, CovaClear, CovaView, CovaWound, IV Clear, SurgiClear, and VALGuard.
COVALON TECHNOLOGIES LTD
1660 Tech Avenue, Unit 5
Mississauga ONTARIO L4W 5S7 CA
CEO: Simon Smith
Employees: 41
Company Website: https://covalon.com/
Investor Relations: http://ir.covalon.com/phoenix.zhtml?c=183092&p=irol-IRHome
Phone: 19055688400
The current stock price of COV.CA is 2.8 CAD. The price decreased by -11.95% in the last trading session.
The exchange symbol of COVALON TECHNOLOGIES LTD is COV and it is listed on the TSX Venture Exchange exchange.
COV.CA stock is listed on the TSX Venture Exchange exchange.
9 analysts have analysed COV.CA and the average price target is 4.49 CAD. This implies a price increase of 60.29% is expected in the next year compared to the current price of 2.8. Check the COVALON TECHNOLOGIES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
COVALON TECHNOLOGIES LTD (COV.CA) has a market capitalization of 76.72M CAD. This makes COV.CA a Micro Cap stock.
COVALON TECHNOLOGIES LTD (COV.CA) currently has 41 employees.
COVALON TECHNOLOGIES LTD (COV.CA) has a resistance level at 3.05. Check the full technical report for a detailed analysis of COV.CA support and resistance levels.
The Revenue of COVALON TECHNOLOGIES LTD (COV.CA) is expected to grow by 11.77% in the next year. Check the estimates tab for more information on the COV.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
COV.CA does not pay a dividend.
COVALON TECHNOLOGIES LTD (COV.CA) will report earnings on 2025-05-27.
The PE ratio for COVALON TECHNOLOGIES LTD (COV.CA) is 25.45. This is based on the reported non-GAAP earnings per share of 0.11 and the current share price of 2.8 CAD. Check the full fundamental report for a full analysis of the valuation metrics for COV.CA.
ChartMill assigns a technical rating of 3 / 10 to COV.CA. When comparing the yearly performance of all stocks, COV.CA is one of the better performing stocks in the market, outperforming 86.01% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to COV.CA. COV.CA scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months COV.CA reported a non-GAAP Earnings per Share(EPS) of 0.11. The EPS increased by 159.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 8.57% | ||
ROA | 8.39% | ||
ROE | 9.71% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 84% to COV.CA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -69.23% and a revenue growth 11.77% for COV.CA